Status:
RECRUITING
Non-invasive Tools for PSVD Diagnosis
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Non-Cirrhotic Portal Hypertension
Porto-Sinusoidal Vascular Diseases
Eligibility:
All Genders
18-80 years
Brief Summary
Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guidi...
Detailed Description
PSVD is a supplement to non-cirrhotic portal hypertension and is defined as a class of diseases with characteristic pathological changes based on portal vein or hepatic sinuses abnormalities without c...
Eligibility Criteria
Inclusion
- Received platinum chemotherapy for organ tumors;
- Ages 18-80;
- sign the informed consent voluntarily.
Exclusion
- Liver pathology suggested cirrhosis;
- Underwent liver transplantation;
- Combined with hepatocellular carcinoma exceeding Milan criteria;
- Complicated with severe heart, kidney, or lung failure;
- Pregnant or lactating women;
- Data is seriously missing;
- Patients were judged not suitable for participation in this study by the researchers.
Key Trial Info
Start Date :
February 28 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06500403
Start Date
February 28 2024
End Date
December 31 2029
Last Update
July 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang hospital, Southern Medical Uiversity
Guangzhou, Guangdong, China, 510080